Complexa is raising a $7-10MM series B open to angel investors, to fund data requested by a pharma needed for an exit/partnership in 18 mos.
Complexa, Inc is a platform anti-inflammatory company utilizing endogenous mediators that signal the body' s main anti-inflammatory pathways. The company’s lead compound is scheduled to enter the clinic in 3Q13 to treat a form of kidney disease. Comparables (e.g.: Reata) have partnered with similar phase data with collective deal values of nearly $1B. Complexa is raising funds for studies requested by a partner needed to exit